InSite's AzaSite cleared in Canada for pink eye

US opthalmic care specialist InSite Vision's AzaSite (azithromycin ophthalmic solution) 1% has been approved in Canada for the treatment of  bacterial conjunctivitis in adults and children aged one year and older.

AzaSite is formulated with DuraSite, InSite's patented drug-delivery  vehicle that enhances the retention time of the antibiotic on the  surface of the eye, offering the benefit of a less frequent and more  convenient dosing regimen.

AzaSite was approved for the treatment of bacterial conjunctivitis by  the US Food and Drug Administration in April 2007, and commercially  launched that August by Inspire Pharmaceuticals, based in Durham, North  Carolina, and exclusive licensee of AzaSite in North America. Under the  terms of the companies' agreement, the Canadian rights to the agent will  transfer to Inspire which will be responsible for marketing AzaSite in  that country.